

Novel free-radical mediated Lipid Peroxidation Biomarkers in Newborn Plasma

Ángel Sánchez-Illana^a, Sudhin Thayyil^b, Paolo Montaldo^b, Dorothea Jenkins^c, Guillermo Quintás^{d,e}, Camille Oger^f, Jean-Marie Galano^f, Claire Vigor^f, Thierry Durand^f, Máximo Vento^{a,g},
Julia Kuligowski^{a,*}

^aNeonatal Research Group, Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain

^bCentre for Perinatal Neuroscience, Imperial College London, UK

^cDepartment of Pediatrics, Medical University of South Carolina, USA

^dBioanalysis and Metabolomics, Leitat Technological Center, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain

^eUnidad Analítica, Health Research Institute La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain

^fInstitut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, Montpellier, France

^gDivision of Neonatology, University & Polytechnic Hospital La Fe, Avenida Fernando Abril Martorell 106, Valencia, Spain

*E-mail: julia.kuligowski@uv.es; Tel: +34-961246661

Abstract

Oxidative stress derived from perinatal asphyxia appears to be closely linked to neonatal brain damage and lipid peroxidation biomarkers have shown to provide predictive power of oxidative stress related pathologies in situations of hypoxia and reoxygenation in the newborn. The objective of this work was to develop and validate of a comprehensive liquid chromatography tandem mass spectrometry approach for the quantitative profiling of 28 isoprostanooids in newborn plasma samples covering a broad range of lipid peroxidation product classes. The method was developed taking into account the specific requirements for its use in neonatology (i.e. limited sample volumes, straightforward sample processing and high analytical throughput). The method was validated following stringent FDA guidelines and was then applied to the analysis of 150 plasma samples collected from newborns. Information obtained from the

quantitative analysis of isoprostanoids was critically compared to that provided by a previously developed approach aiming at the semi-quantitative detection of total parameters of fatty acid derived lipid peroxidation biomarkers.

Keywords: *oxidative stress biomarkers; lipid peroxidation; ultra-performance liquid chromatography coupled to tandem mass spectrometry; plasma; hypoxic-ischemic encephalopathy; newborn*

Abbreviations

p_aO₂ – arterial partial pressure of oxygen

ROS – reactive oxygen species

OS – oxidative stress

HIE – hypoxic-ischemic encephalopathy

IsoPs – isoprostanes

COX – cyclooxygenase

AA – arachidonic acid

NeuroPs – neuroprostanes

DHA – docosahexaenoic acid

AdA – adrenic acid

IsoFs – isofurans

NeuroFs – neurofurans

PGs – prostaglandins

NAC – N-acetylcysteine

QC – quality control

1. Introduction

Fetal life develops in a relatively hypoxic environment with an *in utero* arterial partial pressure of oxygen (p_aO_2) of approximately 3.3 kPa. After birth and with the initiation of spontaneous respiratory alveolar-capillary gas exchange, the situation changes abruptly and p_aO_2 saturation in the circulating blood stream rises to approximately 10.5 kPa within the first minutes of life [1]. During the fetal-to-neonatal transition, a burden of reactive oxygen species (ROS) causes physiologic oxidative stress (OS) essential for the activation of specific metabolic pathways which enable an adequate adaptation to the extra-uterine environment [2].

Perinatal asphyxia is characterized by intermittent periods of hypoxia-ischemia and is considered an important cause of early neonatal death and severe neurological sequel such as hypoxic-ischemic encephalopathy (HIE) and cerebral palsy [3]. Both hypoxia and reoxygenation can generate ROS exceeding the levels observed under physiologic conditions during the fetal-to-neonatal transition which may react with non-radical macromolecules such as DNA, proteins and lipids [4]. OS appears to play a key role in neonatal brain damage, with the neonatal brain being especially susceptible because of its high concentration of unsaturated fatty acids, high rate of oxygen consumption, low concentration of antioxidants, and high iron levels [5].

Isoprostanes (IsoPs) are non-cyclooxygenase (COX) derived, prostaglandin-like molecules generated by the free radical-induced peroxidation of arachidonic acid (AA) [6]. Initially IsoPs are produced in esterified form attached to phospholipids, and then released into body fluids in free form. Today, they are considered the gold standard for *in vivo* assessment of lipid peroxidation due to their stability, selectivity and specificity [7–9]. Following similar mechanisms of non-enzymatic oxygenation, neuroprostanes (NeuroPs) and dihomo-IsoPs are generated from docosahexaenoic acid (DHA) and adrenic acid (AdA), respectively. In addition, when conditions switch to high oxygen tensions, isofurans (IsoFs) and neurofurans (NeuroFs) may be preferentially produced from AA and DHA, respectively [10,11].

The role of lipid peroxidation in pathologies of the neonate has been reviewed [12,13]. It was found that preterm infants with high urinary IsoF levels in the first days after birth are more prone to develop chronic lung conditions such as bronchopulmonary dysplasia as compared to a control group [14]. In a preliminary case study, the potential of lipid peroxidation byproducts as biomarkers for HIE have been studied and significantly increased concentrations of IsoPs were found for newborns with severe postnatal acidemia [15].

Literature reports three primary analytical techniques for the determination of isoprostanoids in biological fluids and tissue extracts including (i) immunological methods such as radioimmunoassay and enzyme linked immunosorbent assay, (ii) gas chromatography coupled to mass spectrometry (MS) and (iii) liquid chromatography coupled to MS (LC-MS). Results obtained from immunoassays might be potentially biased due to the use of polyclonal antibodies and the high structural similarities between IsoPs and COX-derived prostaglandins as well as other related molecules. Furthermore this technique is intrinsically limited as it does not allow differentiation between isomers. In contrast, MS-based assays are widely accepted as the most accurate methodologies [7,16,17]. LC coupled to tandem MS (LC-MS/MS) presents interesting advantages over GC-MS. It does not require long derivatization processes thus reducing the possibility of introducing additional sources of error. Moreover, the use of Ultra-high Performance Liquid Chromatography tandem mass spectrometry (UPLC-MS/MS) involves rapid chromatographic separations. UPLC-MS/MS offers suitable selectivity and sensitivity combined with a high sample throughput for which it has gained popularity recently in this field, especially for clinical applications [14,18–21].

In clinical studies, the choice of the biological fluid is of major concern. Urine samples are suitable for a long-term survey of lipid peroxidation biomarkers of up to several days or weeks after an insult or intervention and allow repeated sampling, but the main pitfall is its limited time resolution and it might not be optimal when the objective is the analysis of early, fast responses in e.g. time-critical therapies. Conversely, blood reflects the dynamic metabolic

response immediately improving time resolution. On the other hand, blood collection is an invasive procedure and the use of small volumes is mandatory, especially in the field of neonatology.

The objective of this work was the development and validation of a comprehensive analytical approach for isoprostanooids profiling in human plasma samples covering a broad range of lipid peroxidation product classes derived from AA, DHA and AdA. The method was developed to fulfill specific requirements to enable its clinical application in neonatology such as addressing the challenge of limited sample volumes, straightforward sample processing and high analytical throughput. In order to assess the usefulness of the developed method, it was employed for the analysis of 150 plasma samples collected from newborns. Information obtained from quantitative analysis was critically compared to that provided by a previously developed approach aiming at the semi-quantitative of total parameters of IsoPs, IsoFs, NeuroPs and NeuroFs, proposed as disease associated biomarkers in clinical applications.

2. Material and methods

2.1 Standards and reagents

Commercially available IsoPs (2,3-dinor-15-F_{2t}-IsoP, 15-keto-15-E_{2t}-IsoP, 15-keto-15-F_{2t}-IsoP, 15-*epi*-15-F_{2t}-IsoP, 15-E_{2t}-IsoP, 15-F_{2t}-IsoP), prostaglandins (PGs) (PGE₂, PGF_{2α}, 2,3-dinor-11β-PGF_{2α}, 11β-PGF_{2α}, 6-keto-PGF_{1α}), dihomop-G (1a,1b-dihomo-PGF_{2α}) were purchased from Cayman Chemical Company (Ann Arbor, MI, USA), with purities ≥95% as well as deuterated internal standards (IS, PGF_{2α}-d₄ and 15-F_{2t}-IsoP-d₄) with purities ≥98% and incorporation ≥99% deuterated form (d₁-d₄); <1% d₀.

Other analytical standards employed were F₂-IsoPs (5-F_{2t}-IsoP, 5-*epi*-5-F_{2t}-IsoP, 15-*epi*-2,3-dinor-15-F_{2t}-IsoP), F₄-NeuroPs (4-F_{4t}-NeuroP, 4-*epi*-4-F_{4t}-NeuroP, 10-*epi*-10-F_{4t}-NeuroP, 10-F_{4t}-NeuroP, 14(*RS*)-14-F_{4t}-NeuroP), F₄-NeuroF (4(*RS*)-ST-Δ⁵-8-NeuroF), F₂-dihomo-IsoPs (17-F_{2t}-dihomo-IsoP,

17-*epi*-17-F_{2t}-dihomo-IsoP, *Ent*-7(*RS*)-F_{2t}-dihomo-IsoP), and F₂-dihomo-IsoFs (17(*RS*)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF, 7(*RS*)-ST- Δ^8 -11-dihomo-IsoF) synthesized at the *Institut des Biomolécules Max Mosseron* (Montpellier, France) according to previously published procedures [22–29], with purities $\geq 99\%$ and all physical data reported in those published articles confirmed the new structures [22–29].

Potassium hydroxide (KOH) was from Sigma Aldrich Química SA (Madrid, Spain). LC-MS grade solvents (methanol CH₃OH, ethanol, heptane and acetonitrile CH₃CN) were purchased from J.T. Baker (Phillipsburg, NJ, USA). Formic acid (HCOOH, 98%) and ethyl acetate (analytical grade) were from Panreac (Barcelona, Spain). Ultrapure H₂O was generated on a milliQ system from Merck Millipore (Darmstadt, Germany).

2.2 Preparation of stock, working, and standard solutions

Individual stock solutions of solid pure analytical standards at a concentration of 1 mmol L⁻¹ were prepared in ethanol. Individual stock solutions of 15-*epi*-15-F_{2t}-IsoP, 1a,1b-dihomo-PGF_{2 α} , and 2,3-dinor-15-F_{2t}-IsoP standards were purchased in methyl acetate or at concentrations of 2.8, 2.6 and 0.3 mmol L⁻¹, respectively. A 5 μ mol L⁻¹ working solution of the set of target analytes was prepared by mixing adequate volumes of the individual stock solutions followed by evaporation to dryness and dissolution in H₂O (0.1% v/v HCOOH, pH 3):CH₃OH (85:15 v/v). Likewise, an IS working solution containing both IS (PGF_{2 α} -d₄ and 15-F_{2t}-IsoP-d₄) at a concentration of 20 μ mol L⁻¹ each was prepared. Aliquots of the obtained stock and working solutions were stored in capped amber vials at -20 °C to avoid repeated freeze and thaw cycles. Standard solutions used for calibration were prepared on each measurement day from the working solution by serial dilution in H₂O (0.1% v/v HCOOH, pH 3):CH₃OH (85:15 v/v).

2.3 Population

After obtaining informed consent, twenty neonates ≥ 35 weeks gestation with HIE who qualified for cooling were recruited in a dose-finding, phase 0 clinical trial of N-acetylcysteine (NAC) and 1,25(OH)₂vitamin D (calcitriol). This study was approved by the Institutional Review Board at the

Medical University of South Carolina, Charleston. Neonates with stage 2 or 3 HIE were enrolled within 6 h of birth. They received hypothermia (33°C rectal temperature) for 72 h and intravenous administration of NAC 25 or 40 mg/kg by infusion over 1h, q 12h, and calcitriol 0.05 mcg/kg q 12h from enrollment (3-6 h of age) until discharge or 10 days of life. Due to elevated ionized calcium in several subjects, calcitriol dose was decreased to 0.03 mcg/kg q 24h for subjects 11-20. Characteristics of the HIE neonates are presented in Table 1.

Blood was collected in sodium EDTA tubes, centrifuged, and plasma was frozen at -80°C within 15-20 minutes of collection. Samples were obtained before, and 0.5 h, 1 h and 11.5 h after the 1st dose, and peak samples 1h after the 3rd (24-30 h) dose during hypothermia. A second set of blood samples were obtained during normothermia before, and 0.5 h, 1 h and 11.5 h after the 10th or 11th NAC dose on day of life 5-6 (>24 h after rewarming). Aliquots of plasma remained frozen at -80°C, and shipped on dry ice without thawing until analysis.

2.4 Processing of plasma samples

Samples were processed following previously described methods [14,18,19,30,31] with slight modifications. Briefly, 100 µL of plasma were thawed on ice, homogenized and 3 µL of IS working solution (20 µmol L⁻¹) were added. For basic hydrolysis 100 µL of KOH (15% w/v) were added to each sample followed by incubation for 30 min at 40°C with gentle agitation in a WSB-18 water bath from Witeg (Wertheim, Germany). Thereafter, samples were diluted with 700 µL of H₂O:CH₃OH:HCOOH (82.6:14.6:2.8 v/v), homogenized on a Vortex mixer for 5 s and kept on ice for 10 min followed by centrifugation at 16000 x g for 10 min at 4°C.

Solid phase extraction (SPE) employing Discovery® DSC-18 SPE 96-well plates from Sigma-Aldrich (St. Louis, MO, USA) was carried out as follows: SPE cartridges were conditioned with 1 mL CH₃OH followed by 1 mL H₂O (0.1% v/v HCOOH, pH 3) and then diluted samples were loaded into the SPE wells. The washing steps included rinsing of each well with 1 mL H₂O (0.1% v/v HCOOH, pH 3) and 500 µL heptane. Cartridges were dried with room air and sample extracts were eluted with 4×100 µL ethyl acetate which were subsequently evaporated using a miVac

centrifugal vacuum concentrator from Genevac LTD (Ipswich, UK). Sample extracts were dissolved in 60 μL of H_2O (0.1% v/v HCOOH , pH 3): CH_3OH (85:15 v/v) prior to UPLC-MS/MS analysis.

2.5 UPLC-MS/MS analysis

UPLC-MS/MS analysis was carried out employing an Acquity-Xevo TQS system from Waters (Milford, MA, USA) using negative electrospray ionization (ESI^-). Instrumental conditions were selected as follows: capillary voltage was set to 2.9 kV, source temperature was 150 $^\circ\text{C}$, desolvation temperature was 395 $^\circ\text{C}$ and nitrogen cone and desolvation gas flows were set to 150 and 800 L h^{-1} , respectively. Dwell time was set to ensure a minimum of 10 data points per peak. Separation conditions were selected to achieve appropriate chromatographic retention and resolution by using a Waters BEH C18 reversed phase column (2.1 $\times$ 100 mm, 1.7 μm) and a H_2O (0.1 % v/v HCOOH): CH_3CN (0.1% v/v HCOOH) binary gradient. Flow rate, column temperature and injection volume were set at 450 $\mu\text{L min}^{-1}$, 45 $^\circ\text{C}$ and 9 μL , respectively. The gradient with a total run time of 7.0 min was as follows: from 0.0 to 0.1 min 15% v/v CH_3CN (0.1% v/v HCOOH) (i.e. channel B); from 0.1 to 5.0 min %B increased up to 40%; from 5.0 to 6.0 min %B increased up to 75%; between 6.0 and 6.15 conditions were held constant at 75% B followed by the return to initial conditions (i.e. 15% B) between 6.15 and 6.25 min; conditions were maintained for 0.75 min for system re-equilibration.

MS detection was carried out by multiple reaction monitoring (MRM) employing the acquisition parameters summarized in Table 2. The UPLC-MS/MS system was operated employing MassLynx software version 4.0 from Waters. Cone voltages and collision energy values were optimized by analysis of individual 1 μM standard solutions in the UPLC-ESI-MS/MS system. For quantification, linear regression curves with 1/x weighting were calculated including signal normalization with an IS. Concentrations found in plasma samples falling outside the calibration range or showing a shift in retention time bigger than ± 0.05 min in comparison to standard solutions were not further considered. For total parameters (total IsoPs, IsoFs, NeuroPs and NeuroFs), MRM

detection was carried out as previously described [14]. Here, relative signal intensities normalized using the IS signal were determined instead of absolute concentrations in order to avoid the need of pure analytical standards. Total parameters were considered when the area was > 3 times the signal of a blank.

On each measurement day, prior to the launch of the analytical sequence, a system suitability test was carried out including the following criteria: (i) a backpressure ripple <2% at the beginning of the chromatographic run; (ii) absence of the IS peak in a non-spiked plasma sample; (iii) absence of analyte peaks during a blank injection (i.e. H₂O (0.1% v/v COOH)); (iv) appropriate sensitivity and precision during triplicate analysis of a standard solution at the LOQ. Accordingly, %RSD of peak area values should be ≤25% and the signal-to-noise ratios ≥9 for each studied analyte; and (v) retention times within ±0.05 min between consecutive batches. Blank samples and solvent blanks were analyzed at the beginning of the sample batch, after a high concentration standard and repeatedly along the batch in order to check for contamination of the analytical system (i.e. column, mobile phase additives etc.), carryover and cross contamination. A representative quality control (QC) plasma sample was analyzed repeatedly throughout sample batches to detect deviations in accuracy and/or precision. An analysis batch was accepted if at least 75 % of the values found for the QC standards were within ±25 % of their respective nominal values.

2.6 Method validation

During method validation, figures of merit of the sample preparation and measurement procedure including the linearity range, precision, accuracy, selectivity, limit of detection (LOD), limit of quantification (LOQ) and carry-over were assessed. The method validation was based on the US Food and Drug Administration (FDA) guidelines for bioanalytical method validation [32]. However, the FDA guideline aims at the quantitative analysis of drugs and drug metabolites in biological matrices and it cannot be directly applied to the analysis of endogenous metabolites due to the lack of blank matrices. To circumvent this, accuracy and precision of the method were

established by calculating relative recovery values. Therefore, a non-spiked pooled plasma sample was analyzed by triplicate on each validation day. Duplicate analysis of standards at three concentration levels and triplicate analysis of plasma samples spiked before and after SPE at two concentration levels on two measurement days were carried out. The percentage of relative standard deviation (RSD) of replicate standards within one validation batch (intra-day) and between validation batches (inter-day) were calculated to assess precision. Inter-day and intra-day extraction yields were calculated comparing absolute peak areas from samples spiked before and after SPE and the matrix effect was determined by comparing absolute peak areas of samples spiked after SPE to pure analytical standards. Furthermore, the method's overall accuracy and precision for the determination of the studied compounds in plasma were evaluated at two concentration levels by comparing the relative response of spiked samples and pure analytical standards. The LOD and LOQ levels were estimated as the concentrations providing a signal-to-noise ratio of 3 and 10, respectively also providing precision and accuracy levels within the FDA recommended ranges. Selectivity was evaluated by analyzing blanks and a non-spiked pooled plasma sample. The carry-over was determined from the analysis of a blank sample after to the measurement of a concentrated standard solution.

3. Results and discussion

3.1 UPLC-MS/MS method for the determination of lipid peroxidation biomarkers

Ionization and fragmentation conditions for the MS/MS quantification for the set of 28 analytical standards were optimized by analysis of 5 $\mu\text{mol L}^{-1}$ individual standard solutions. Chemical structures of the studied compounds are shown in Supplementary Material Figure 1 and the selected MS/MS acquisition parameters are summarized in Table 2. Chromatographic conditions were also optimized employing a 5 $\mu\text{mol L}^{-1}$ working solution. Specificity of the MRM transitions was assessed by analyzing a set of individual standards employing the proposed LC-MS/MS procedure, which included the recording of 16 MRM transitions. Figure 1 displays representative

LC-MS/MS chromatograms extracted from the analysis of a spiked plasma sample. As shown in the figure, symmetric peak shapes were obtained for the total of 23 resolved peaks, all eluting in a retention time window between 3.71 and 6.06 min. Nonetheless, due to high structural similarities, a reduced number of lipids showed a significant chromatographic and MS overlap that could not be resolved neither by MS/MS nor by changing the chromatographic conditions (see Table 2).

Table 2 summarizes the main analytical figures of merit obtained for the quantification of the selected set of compounds. Highly reproducible retention times with a standard deviations ≤ 0.04 min were observed for the set of metabolites and IS. Linear calibration lines calculated using either PGF_{2 α} -d₄ or 15-F_{2t}-IsoP-d₄ as IS generally covering two to three orders of magnitude were obtained with coefficients of determination (R^2) >0.97 and homoscedastic residuals as assessed by visual inspection. LOD and LOQ expressed as nmol L⁻¹ of plasma were in the 0.11–53 and 0.4–178 range, respectively. No carry-over was observed with peak areas of the blank injection remaining below 5 % of the signal of the standard at the LOD.

Table 3 shows back-calculated recovery values in standard solutions for assessment of accuracy and precision. Adequate accuracies were obtained in standard solutions with the exception of 17(*RS*)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF and 1a,1b-dihomo-PGF_{2 α} . Precision levels remained <20 % at the LOQ and <15 % for higher concentrations, with the exception of the intra-day precision obtained for 15-E_{2t}-IsoP. In Table 4 the method's performance was further assessed by the analysis of spiked plasma samples and calculated recovery values taking into account the concentrations found in the non-spiked sample. The extraction yields were used for jointly assessing the effect of the KOH digestion procedure and the solid phase extraction sample clean-up. Good inter- and intra-day extraction yields ranging between 82 and 115% and 79 and 131% were found for lipid peroxidation products derived from AA and DHA with the exception of four metabolites derived from AA (i.e. 15-keto-15-F_{2t}-IsoP, 15-E_{2t}-IsoP, 15-keto-15-E_{2t}-IsoP and PGE₂), which were not detected. It is suspected that during sample hydrolysis these analytes suffer

dehydration within the β -hydroxy-keto system in the cyclopentane ring (i.e. cyclopentenone PGs) [7] while the δ -hydroxy- α,β -unsaturated-keto system of 15-keto-15-F_{2t}-IsoP is degrading into a reactive conjugated keto-diene system. AdA derived lipid peroxidation products showed lower extraction yields ranging between 52 and 100% and 60 and 95% for inter- and intra-day accuracy, indicating that those compounds are either partially degraded during the digestion step or not completely recovered during the SPE. As observed from Table 4, for a total of seven compounds a notable matrix effect was observed whereas for the remaining compounds intra- and inter-day recoveries ranged between 78-129% and 75-123%, respectively. No pattern between different lipid peroxidation classes could be detected with respect to the matrix effect. Moreover, the overall accuracy and precision of the developed method was assessed for all metabolites which were not degraded during the hydrolysis procedure by means of relative recovery values employing deuterated ISs. For AA and DHA derived lipid peroxidation products obtained intra- and inter-day accuracy levels ranged between 79 and 120 % and 80 and 113%, respectively, with the exception of 4(RS)-ST- Δ^5 -8-NeuroF for which only a semiquantitative determination was achieved despite the use of an IS. Due to the low extraction yields observed for dihom-IsoPs and dihom-IsoFs a semiquantitative determination was proposed to enable the comparison of samples analyzed and extracted under the same conditions. Complementary approaches such as including isotopically labelled analogues of dihom-IsoPs and dihom-IsoFs as surrogates to improve the accuracy of the method are being evaluated. In summary, data shown in Table 4 prove that the developed method is highly reproducible for the analysis of the majority of compounds while it gives insights in the analytical challenges for several other compounds which might be affected during sample processing and measurement.

3.2 Quantitative analysis of lipid peroxidation biomarkers in newborn plasma samples

Lipid peroxidation biomarkers were determined in 150 plasma samples from 20 term newborns suffering from HIE secondary to birth asphyxia (see Table 1) at 10 sampling time points covering from 3 h to 6 days after birth. Table 5 shows the main descriptors of the distribution of

concentrations of the lipid peroxidation products found in the studied samples excluding the four metabolites which were not stable during the sample KOH hydrolysis process (i.e. 15-keto-15-F_{2t}-IsoP, 15-E_{2t}-IsoP, 15-keto-15-E_{2t}-IsoP and PGE₂). From the 17 remaining parameters, 11 (corresponding to 16 individual isoprostanooids) were detected in the studied samples. In addition to the determination of individual lipid peroxidation biomarkers, total relative IsoP, IsoF, NeuroP and NeuroF contents were measured following a procedure as described elsewhere [14]. Three out of the 11 compounds have been detected in a preliminary biomarker study involving a similar cohort of newborns (N=20) [15]. In newborns with HIE undergoing TH concentrations determined were of the same order of magnitude as in this cohort with medians (IQRs) of 3 (12), 5(7) and 0 (3.4) for 5-F_{2t}-IsoP, PGF_{2α} and 1a,1b-dihomo-PGF_{2α}, respectively.

Figure 2 shows boxplots of the results of isoprostanooids which were detected in more than 25% of samples. The results are stratified by two collection time windows, the first one comprising the first 30 h after birth during hypothermia and the second including samples collected on day 5 to 6 during normothermia. Interestingly, not all metabolites showed the same behavior with time. In a previous study the levels of total IsoPs, IsoFs, NeuroPs and NeuroFs were monitored in preterm infants throughout the whole neonatal period and nomograms of relative contents were established revealing the underlying changes of biomarker levels as a function of the infant's age [14]. This might be an important aspect to be taken into account during the experimental design of clinical studies as well as during the interpretation of the results. Here, a significant decrease with time was detected for some metabolites (i.e. 5-F_{2t}-IsoP + 5-*epi*-5-F_{2t}-IsoP, PGF_{2α}, total NeuroFs), whereas others increased (i.e. 17(*RS*)-10-*epi*-SC-Δ¹⁵-11-dihomo-IsoF, 7(*RS*)-ST-Δ⁸-11-dihomo-IsoF, total NeuroPs) or remained unchanged (1a,1b-dihomo-PGF_{2α}, total IsoFs). This application illustrates the strengths of a detection method which is able to detect and quantify specific isomers as compared to the determination of total parameters. Also, the specific detection of isomers enables an absolute quantification, which at the same time improves the method's sensitivity. This is also demonstrated in the present study by the

detection of IsoPs: whereas for total IsoPs the concentrations remained below the LOQ, some individual IsoPs could still be detected (i.e. 5-F_{2t}-IsoP + 5-*epi*-5-F_{2t}-IsoP). Conversely, for IsoFs no analytical standard solutions were available and the determination of total IsoFs enabled the detection of these metabolites in plasma samples. Likewise, in case of NeuroPs and NeuroFs, individual isomers could not be detected in the majority of samples, whereas for the total parameters levels above the LOQ were found, indicating that the individual isomers included in this method might not be those which were formed primarily. Hence, the simultaneous determination of both, individual isomers and total parameters is recommended for studying lipid peroxidation biomarkers in biofluids. Whereas the individual isomers give a more detailed information on the lipid peroxidation process providing insight into the underlying mechanisms of action, total parameters are a straightforward alternative when no pure analytical standard solutions are available. Moreover, even if the determination of individual isomers was not limited by the availability of standards, it would not be feasible to resolve and determine all possible isomers in one analytical run. Therefore, it would first have to be established which lipid peroxidation biomarkers are of interest for monitoring in each study in dependence of the species, biofluid and pathophysiological situation.

4. Conclusions

This work presents the first validated LC-MS/MS method for the simultaneous quantification of 28 lipid peroxidation biomarkers in addition to four total relative parameters in small volumes (100 µL) of plasma samples. The access to a considerable panel of different isomers allowed an in-depth study of the effect of analytical and pre-analytical conditions on the determination of the metabolites revealing stability issues in 4 metabolites during hydrolysis. Future studies will focus on the modification of the hydrolysis conditions e.g. using enzymatic hydrolysis. Furthermore the use of isotopically labelled internal standards for each studied substance class as surrogates is recommended to improve the method's accuracy.

The validated method was applied to a total of 150 plasma samples from newborns, with small sample volumes of between 40 and 100 μ L available. The obtained results revealed changes in some of the detected biomarkers with time, whereas others remained constant. In the present study, samples were stored without the addition of antioxidants as recommended in the literature [17]. Future work focusing on a systematic evaluation of the effect of storage and the use of antioxidants will be necessary for implementing a reliable protocol for the determination of lipid peroxidation biomarkers in clinical studies. The advantages and pitfalls of the detection of total relative parameters in comparison to individual isomers have been critically discussed and the simultaneous use of both detection approaches is encouraged.

Acknowledgements

The project received funding from the *Instituto Carlos III* (FISPI14/0433), Spanish Ministry of Health, Social Services and Equality (EC11-246), and Institute of Translational Medicine & Therapeutics (ITMAT), National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), Imperial College London (P60743). Furthermore, the authors acknowledge financial support from the Research Network on Maternal and Child Health and Development Retic Red SAMID RD12/0026/11 and FEDER funding from the European Union (*Instituto Carlos III*, Ministry of Economy and Competitiveness, Spain). JK acknowledges funding from the *Conselleria de Educaci3n, Investigaci3n, Cultura y Deporte* of the *Generalitat Valenciana* (GV 2016/062). JK and ASI are grateful for their personal *Miguel Servet* and PFIS grants (CP16/00034 and FI16/00380) provided by the *Instituto Carlos III* (Ministry of Economy and Competitiveness, Spain).

References

- [1] I. Torres-Cuevas, M. Cernada, A. Nuñez, J. Escobar, J. Kuligowski, C. Chafer-Pericas, M. Vento, Oxygen Supplementation to Stabilize Preterm Infants in the Fetal to Neonatal Transition: No Satisfactory Answer, *Front. Pediatr.* 4 (2016). doi:10.3389/fped.2016.00029.
- [2] J. Belik, G.E. González-Luis, F. Perez-Vizcaino, E. Villamor, Isoprostanes in fetal and neonatal health and disease, *Free Radic. Biol. Med.* 48 (2010) 177–188. doi:10.1016/j.freeradbiomed.2009.10.043.
- [3] N. Merchant, D. Azzopardi, Early predictors of outcome in infants treated with hypothermia for hypoxic-ischaemic encephalopathy, *Dev. Med. Child Neurol.* 57 Suppl 3 (2015) 8–16. doi:10.1111/dmcn.12726.
- [4] Vento, M, Hummler, H, Dawson, J, Escobar, J, Kuligowski, J, Use of Oxygen in the Resuscitation of Neonates, in: Dennery, PA, Buonocore, G, Saugstad, OD (Eds.), *Perinat. Prenat. Disord.*, Humana Press, New York, 2014: pp. 213–244.
- [5] R. Solberg, M. Longini, F. Proietti, P. Vezzosi, O.D. Saugstad, G. Buonocore, Resuscitation with supplementary oxygen induces oxidative injury in the cerebral cortex, *Free Radic. Biol. Med.* 53 (2012) 1061–1067. doi:10.1016/j.freeradbiomed.2012.07.022.
- [6] J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, L.J. Roberts 2nd, A series of prostaglandin F₂-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism, *Proc. Natl. Acad. Sci. U. S. A.* 87 (1990) 9383–9387.
- [7] G.L. Milne, Q. Dai, L.J. Roberts, The isoprostanes--25 years later, *Biochim. Biophys. Acta.* 1851 (2015) 433–445. doi:10.1016/j.bbalip.2014.10.007.
- [8] G.L. Milne, H. Yin, K.D. Hardy, S.S. Davies, L.J. Roberts 2nd, Isoprostane generation and function, *Chem. Rev.* 111 (2011) 5973–5996. doi:10.1021/cr200160h.
- [9] U. Jahn, J.-M. Galano, T. Durand, Beyond prostaglandins--chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids, *Angew. Chem. Int. Ed Engl.* 47 (2008) 5894–5955. doi:10.1002/anie.200705122.
- [10] W.-L. Song, J.A. Lawson, D. Reilly, J. Rokach, C.-T. Chang, B. Giasson, G.A. FitzGerald, Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid, *J. Biol. Chem.* 283 (2008) 6–16. doi:10.1074/jbc.M706124200.
- [11] H.-C. Yen, H.-J. Wei, C.-L. Lin, Unresolved issues in the analysis of F₂-isoprostanes, F₄-neuroprostanes, isofurans, neurofurans, and F₂-dihomo-isoprostanes in body fluids and tissue using gas chromatography/negative-ion chemical-ionization mass spectrometry, *Free Radic. Res.* 49 (2015) 861–880. doi:10.3109/10715762.2015.1014812.
- [12] S. Perrone, M.L. Tataranno, G. Stazzoni, G. Buonocore, Biomarkers of oxidative stress in fetal and neonatal diseases, *J. Matern. Fetal Neonatal Med.* 25 (2012) 2575–2578. doi:10.3109/14767058.2012.718004.
- [13] G. Tonni, S. Leoncini, C. Signorini, L. Ciccoli, C.D. Felice, Pathology of perinatal brain damage: background and oxidative stress markers, *Arch. Gynecol. Obstet.* 290 (2014) 13–20. doi:10.1007/s00404-014-3208-6.
- [14] J. Kuligowski, M. Aguar, D. Rook, I. Lliso, I. Torres-Cuevas, J. Escobar, G. Quintás, M. Brugada, Á. Sánchez-Illana, J.B. van Goudoever, M. Vento, Urinary Lipid Peroxidation Byproducts: Are They Relevant for Predicting Neonatal Morbidity in Preterm Infants?, *Antioxid. Redox Signal.* 23 (2015) 178–184. doi:10.1089/ars.2015.6262.
- [15] C. Chafer-Pericas, M. Cernada, L. Rahkonen, V. Stefanovic, S. Andersson, M. Vento, Preliminary case control study to establish the correlation between novel peroxidation biomarkers in cord serum and the severity of hypoxic ischemic encephalopathy, *Free Radic. Biol. Med.* 97 (2016) 244–249. doi:10.1016/j.freeradbiomed.2016.06.006.
- [16] Y.Y. Lee, J.-M. Galano, C. Oger, C. Vigor, R. Guillaume, J. Roy, J.-Y. Le Guennec, T. Durand, J.C.-Y. Lee, Assessment of Isoprostanes in Human Plasma: Technical Considerations and

the Use of Mass Spectrometry, *Lipids*. 51 (2016) 1217–1229. doi:10.1007/s11745-016-4198-x.

- [17] G.L. Milne, B. Gao, E.S. Terry, W.E. Zackert, S.C. Sanchez, Measurement of F2- isoprostanes and isofurans using gas chromatography-mass spectrometry, *Free Radic. Biol. Med.* 59 (2013) 36–44. doi:10.1016/j.freeradbiomed.2012.09.030.
- [18] C. Cháfer-Pericás, L. Rakkonen, A. Sánchez-Illana, J. Kuligowski, I. Torres-Cuevas, M. Cernada, E. Cubells, A. Nuñez-Ramiro, S. Andersson, M. Vento, J. Escobar, Ultra high performance liquid chromatography coupled to tandem mass spectrometry determination of lipid peroxidation biomarkers in newborn serum samples, *Anal. Chim. Acta.* 886 (2015) 214–220. doi:10.1016/j.aca.2015.06.028.
- [19] C. Cháfer-Pericás, I. Torres-Cuevas, A. Sanchez-Illana, J. Escobar, J. Kuligowski, R. Solberg, H.T. Garberg, M.U. Huun, O.D. Saugstad, M. Vento, Development of a reliable analytical method to determine lipid peroxidation biomarkers in newborn plasma samples, *Talanta*. 153 (2016) 152–157. doi:10.1016/j.talanta.2016.03.010.
- [20] A. Dupuy, P. Le Faouder, C. Vigor, C. Oger, J.-M. Galano, C. Dray, J.C.-Y. Lee, P. Valet, C. Gladine, T. Durand, J. Bertrand-Michel, Simultaneous quantitative profiling of 20 isoprostanooids from omega-3 and omega-6 polyunsaturated fatty acids by LC-MS/MS in various biological samples, *Anal. Chim. Acta.* 921 (2016) 46–58. doi:10.1016/j.aca.2016.03.024.
- [21] I. De Las Heras-Gómez, S. Medina, T. Casas-Pina, L. Marín-Soler, A. Tomás, P. Martínez-Hernández, C. Oger, J.-M. Galano, T. Durand, L. Jimeno, S. Llorente, E. Lozoya, F. Ferreres, Á. Gil-Izquierdo, Potential applications of lipid peroxidation products - F4-neuroprostanes, F3-neuroprostanes-6 DPA, F2-dihomo-isoprostanes and F2-isoprostanes - in the evaluation of the allograft function in renal transplantation, *Free Radic. Biol. Med.* 104 (2017) 178–184. doi:10.1016/j.freeradbiomed.2017.01.019.
- [22] T. Durand, A. Guy, O. Henry, J.-P. Vidal, J.-C. Rossi, C. Rivalta, A. Valagussa, C. Chiabrando, Total Syntheses of Four Metabolites of 15-F2t-Isoprostane, *Eur. J. Org. Chem.* 2001 (2001) 809–819. doi:10.1002/1099-0690(200102)2001:4<809::AID-EJOC809>3.0.CO;2-6.
- [23] D. T, C. JI, G. A, R. Jc, Syntheses and preliminary pharmacological evaluation of the two epimers of the 5-F2t-isoprostane., *Bioorg. Med. Chem. Lett.* 11 (2001) 2495–2498. doi:10.1016/S0960-894X(01)00473-5.
- [24] Total synthesis of 4(RS)-F4t-isoprostane methyl ester | Thierry Durand - Academia.edu, (n.d.). http://www.academia.edu/13386671/Total_synthesis_of_4_RS_-F4t-isoprostane_methyl_ester (accessed May 26, 2017).
- [25] C. Oger, V. Bultel-Poncé, A. Guy, L. Balas, J.-C. Rossi, T. Durand, J.-M. Galano, The handy use of Brown's P2-Ni catalyst for a skipped diyne deuteration: application to the synthesis of a [D4]-labeled F4t-neuroprostane, *Chem. Weinh. Bergstr. Ger.* 16 (2010) 13976–13980. doi:10.1002/chem.201002304.
- [26] C. Oger, V. Bultel-Poncé, A. Guy, T. Durand, J.-M. Galano, Total Synthesis of Isoprostanes Derived from Adrenic Acid and EPA, *Eur. J. Org. Chem.* 2012 (2012) 2621–2634. doi:10.1002/ejoc.201200070.
- [27] A. Guy, C. Oger, J. Heppekausen, C. Signorini, C. De Felice, A. Fürstner, T. Durand, J.-M. Galano, Oxygenated metabolites of n-3 polyunsaturated fatty acids as potential oxidative stress biomarkers: total synthesis of 8-F3t-IsoP, 10-F4t-NeuroP and [D4]-10-F4t-NeuroP, *Chem. Weinh. Bergstr. Ger.* 20 (2014) 6374–6380. doi:10.1002/chem.201400380.
- [28] A. de La Torre, Y.Y. Lee, C. Oger, P.T. Sangild, T. Durand, J.C.-Y. Lee, J.-M. Galano, Synthesis, Discovery, and Quantitation of Dihomo-Isofurans: Biomarkers for In Vivo Adrenic Acid Peroxidation, *Angew. Chem. Int. Ed.* 53 (2014) 6249–6252. doi:10.1002/anie.201402440.
- [29] A. de la Torre, Y.Y. Lee, A. Mazzoni, A. Guy, V. Bultel-Poncé, T. Durand, C. Oger, J.C.-Y. Lee, J.-M. Galano, Total Syntheses and In Vivo Quantitation of Novel Neurofuran and Dihomo-isofuran Derived from Docosahexaenoic Acid and Adrenic Acid, *Chem. – Eur. J.* 21 (2015) 2442–2446. doi:10.1002/chem.201405497.

- [30] J. Kuligowski, J. Escobar, G. Quintás, I. Lliso, I. Torres-Cuevas, A. Nuñez, E. Cubells, D. Rook, J.B. van Goudoever, M. Vento, Analysis of lipid peroxidation biomarkers in extremely low gestational age neonate urines by UPLC-MS/MS, *Anal. Bioanal. Chem.* 406 (2014) 4345–4356. doi:10.1007/s00216-014-7824-6.
- [31] N.E. Bastani, T.E. Gundersen, R. Blomhoff, Determination of 8-epi PGF2 α concentrations as a biomarker of oxidative stress using triple-stage liquid chromatography/tandem mass spectrometry, *Rapid Commun. Mass Spectrom.* 23 (2009) 2885–2890. doi:10.1002/rcm.4197.
- [32] Food and Drug Administration (FDA), Guidance for industry: bioanalytical method validation, (2001).

Legends of Figures

Figure 1. Chromatograms of lipid peroxidation products of AA+PGs (top, left), DHA (top, right), AAd (bottom, left) and IS (bottom, right) detected in a spiked plasma sample. Note: 1 = 5-F_{2t}-IsoP + 5-*epi*-5-F_{2t}-IsoP; 2 = 15-*epi*-2,3-dinor-15-F_{2t}-IsoP + 2,3-dinor-11 β -PGF_{2 α} + 2,3-dinor-15-F_{2 α} -IsoP; 3 = 15-keto-15-F_{2t}-IsoP; 4 = 15-*epi*-15-F_{2t}-IsoP; 5 = 15-F_{2t}-IsoP; 6 = 11 β -PGF_{2 α} ; 7 = PGF_{2 α} ; 8 = 15-E_{2t}-IsoP; 9 = PGE₂; 10 = 6-keto-PGF_{1 α} ; 11 = 15-keto-15-E_{2t}-IsoP; 12 = 4-F_{4t}-NeuroP + 4-*epi*-4-F_{4t}-NeuroP; 13 = 10-*epi*-10-F_{4t}-NeuroP; 14 = 10-F_{4t}-NeuroP; 15 = 14(*RS*)-14-F_{4t}-NeuroP; 16 = 4(*RS*)-ST- Δ^5 -8-NeuroF; 17 = 17-F_{2t}-dihomo-IsoP + 17-*epi*-17-F_{2t}-dihomo-IsoP; 18 = 1a,1b-dihomo-PGF_{2 α} ; 19 = *Ent*-7(*RS*)-F_{2t}-dihomo-IsoP; 20 = 17(*RS*)-10-*epi*-SC- Δ^{15} -11-dihomo-IsoF; 21 = 7(*RS*)-ST- Δ^8 -11-dihomo-IsoF; 22 = PGF_{2 α} -d₄; 23 = 15-F_{2t}-IsoP-d₄; Chromatograms have been normalized to the maximum intensity of the highest detected peak; chromatograms have been shifted in the y-direction for a better visibility.

Figure 2. Boxplots of isoprostanooids in plasma samples from newborns on days 1 and 5. Boxes indicate the 1st and the 3rd quartiles, the median is shown as a blue line, whiskers mark the 9th and 91st percentiles, red triangles represent mean concentrations and blue circles are outliers
Note: Values below LOQ were replaced by ½ LOQ; ** = p-value < 0.01

Table 1. Characteristics of the studied population.

Variable	Value
Male/female	11/9
Mean gestational age $\pm$ s (weeks)	38.3 ± 1.7
Mean birth weight $\pm$ s (g)	3290 ± 460
Vaginal/C-section	5/15
Mean cord pH $\pm$ s	6.9 ± 0.2
Mean base excess $\pm$ s (mEqL ⁻¹)	-17.0 ± 8.8
Mean lactate $\pm$ s (mM)	9.1 ± 5.0
Mean Apgar score $\pm$ s at 1 min	1.2 ± 1.2
Mean Apgar score $\pm$ s at 5 min	3.2 ± 2.2
Mean Apgar score $\pm$ s at 10 min	5.5 ± 2.2

Table 2. Acquisition parameters and main figures of merit of the LC-MS/MS method.

# ^a	Analyte	m/z Parent ion	Cone [V]	CE [eV]	m/z Daughter ions	RT ± s (min)	Calibration range (nM)	R ²	LOD (nM)	LOQ (nM)	Internal standard
1	5-F _{2t} -IsoP + 5- <i>epi</i> -5-F _{2t} -IsoP	353.20	35	30	115.00	5.09 ± 0.03	3.5 - 3562.5	0.991	0.6	2	PGF _{2α} -d4
	15- <i>epi</i> -2,3-dinor-15-F _{2t} -IsoP +	325.27	40	13	237.00	3.71 ± 0.04	1.7 - 3562.5	0.998	0.3	1.0	15-F _{2t} -IsoP-d4
2	2,3-dinor-11β-PGF _{2α} +										
	2,3-dinor-15-F _{2α} -IsoP										
12	4-F _{4t} -NeuroP +	377.32	20	19	271.12	5.70 ± 0.03	1.7 - 3562.5	0.996	0.3	1.0	PGF _{2α} -d4
	4- <i>epi</i> -4-F _{4t} -NeuroP										
13	10- <i>epi</i> -10-F _{4t} -NeuroP	377.32	10	19	153.00	5.17 ± 0.03	0.6 - 1187.5	0.994	0.11	0.4	PGF _{2α} -d4
14	10-F _{4t} -NeuroP	377.32	10	19	153.00	5.02 ± 0.03	0.6 - 1187.5	0.998	0.11	0.4	15-F _{2t} -IsoP-d4
15	14(<i>RS</i>)-14-F _{4t} -NeuroP	377.32	50	19	204.89	5.33 ± 0.03	9.3 - 1187.5	0.993	2	6	PGF _{2α} -d4
16	4(<i>RS</i>)-ST-Δ ⁵ -8-NeuroF	393.60	40	35	123.19	5.78 ± 0.03	296.9 - 4750	0.973	53	178	PGF _{2α} -d4
17	17-F _{2t} -dihomo-IsoP + 17- <i>epi</i> -17-F _{2t} -dihomo-IsoP	381.30	20	25	337.15	5.80 ± 0.02	1.2 - 2375	0.997	0.2	0.7	PGF _{2α} -d4
19	<i>ent</i> -7(<i>RS</i>)-F _{2t} -dihomo-IsoP	381.30	50	25	142.98	5.83 ± 0.02	0.6 - 1187.5	0.990	0.11	0.4	PGF _{2α} -d4
20	17(<i>RS</i>)-10- <i>epi</i> -SC-Δ ¹⁵ -11-dihomo-IsoF	397.40	20	31	155.02	6.06 ± 0.01	0.6 - 1187.5	0.994	0.11	0.4	PGF _{2α} -d4
21	7(<i>RS</i>)-ST-Δ ⁸ -11-dihomo-IsoF	397.40	40	25	201.03	6.06 ± 0.01	148.4 - 4750	0.984	27	89	PGF _{2α} -d4
3	15-keto-15-F _{2t} -IsoP	351.00	35	25	289.00	5.13 ± 0.04	1.2 - 1187.5	0.995	0.2	0.7	PGF _{2α} -d4
18	1a,1b-dihomo-PGF _{2α}	381.30	20	25	337.15	6.01 ± 0.01	1.2 - 1187.5	0.994	0.2	0.7	15-F _{2t} -IsoP-d4
5	15-F _{2t} -IsoP	353.00	35	30	193.00	4.83 ± 0.03	2.3 - 1187.5	0.997	0.4	1.4	15-F _{2t} -IsoP-d4
8	15-E _{2t} -IsoP	351.00	35	30	271.00	5.35 ± 0.03	9.2 - 1187.5	0.990	2	6	PGF _{2α} -d4
6	11β-PGF _{2α}	353.00	35	30	193.00	4.93 ± 0.03	1.2 - 1187.5	0.998	0.2	0.7	15-F _{2t} -IsoP-d4
4	15- <i>epi</i> -15-F _{2t} -IsoP	353.00	35	30	193.00	4.76 ± 0.03	2.3 - 1187.5	0.998	0.4	1.4	15-F _{2t} -IsoP-d4
10	6-keto-PGF _{1α}	369.00	40	35	245.00	3.97 ± 0.03	0.6 - 1187.5	0.997	0.11	0.4	15-F _{2t} -IsoP-d4
7	PGF _{2α}	353.00	35	30	193.00	5.24 ± 0.03	0.6 - 1187.5	0.993	0.11	0.4	PGF _{2α} -d4
11	15-keto-15-E _{2t} -IsoP	349.00	40	30	113.00	5.73 ± 0.03	2.3 - 1187.5	0.996	0.4	1.4	PGF _{2α} -d4
9	PGE ₂	351.00	35	30	271.00	5.42 ± 0.04	2.3 - 1187.5	0.992	0.4	1.4	PGF _{2α} -d4
22	PGF _{2α} -d ₄	357.00	40	30	197.00	5.24 ± 0.03	-	-	-	-	-
23	15-F _{2t} -IsoP -d ₄	357.00	40	30	197.00	4.81 ± 0.03	-	-	-	-	-
-	Isoprostanes	353.20	35	30	115.00	4.0-6.3	-	-	-	-	PGF _{2α} -d4
-	Isofurans	369.20	45	20	115.00	1.9-6.3	-	-	-	-	PGF _{2α} -d4
-	Neuroprostanes	377.00	35	20	101.00	2.0-6.2	-	-	-	-	PGF _{2α} -d4
-	Neurofurans	393.00	35	20	193.00	2.4-6.2	-	-	-	-	PGF _{2α} -d4

Note: ^a indicates the peak number according to Figure 1; LOQs were established as the concentration of analyte that can be measured with an imprecision of less than 20% and a deviation from target of less than 20% and taking into account the preconcentration factor achieved during sample processing. The LOD is defined as 3/10*LOQ.

Table 3. Back-calculated intra- and inter-day accuracy and precision of standard solutions.

# ^a	Analyte	Standard solutions - % Accuracy $\pm$ RSD (conc nM)					
		Intra-day (N=3)			Inter-day (N=2)		
		Low	Medium	High	Low	Medium	High
1	5-F _{2t} -IsoP + 5- <i>epi</i> -5-F _{2t} -IsoP	96 $\pm$ 6 (3.5)	110 $\pm$ 10 (111.3)	98 $\pm$ 9 (3562.5)	100.6 $\pm$ 7 (3.5)	107 $\pm$ 9 (111.3)	100 $\pm$ 7 (3562.5)
2	15- <i>epi</i> -2,3-dinor-15-F _{2t} -IsoP + 2,3-dinor-11 β -PGF _{2α} + 2,3-dinor-15-F _{2α} -IsoP	89 $\pm$ 4 (1.7)	108 $\pm$ 2 (111.3)	101.8 $\pm$ 8 (3562.5)	93 $\pm$ 15 (1.7)	115 $\pm$ 8 (111.3)	98 $\pm$ 5 (3562.5)
12	4-F _{4t} -NeuroP + 4- <i>epi</i> -4-F _{4t} -NeuroP	80 $\pm$ 8 (1.7)	105 $\pm$ 5 (111.3)	97 $\pm$ 1 (3562.5)	82.6 $\pm$ 8 (1.7)	105 $\pm$ 5 (111.3)	98 $\pm$ 2 (3562.5)
13	10- <i>epi</i> -10-F _{4t} -NeuroP	110 $\pm$ 10 (0.6)	99.3 $\pm$ 5 (37.1)	101 $\pm$ 8 (1187.5)	111 $\pm$ 9 (0.6)	96 $\pm$ 5 (37.1)	104 $\pm$ 7 (1187.5)
14	10-F _{4t} -NeuroP	112 $\pm$ 12 (0.6)	103 $\pm$ 10 (37.1)	100 $\pm$ 5 (1187.5)	120 $\pm$ 14 (0.6)	100 $\pm$ 8 (37.1)	101.9 $\pm$ 7 (1187.5)
15	14(<i>RS</i>)-14-F _{4t} -NeuroP	110 $\pm$ 20 (9.3)	99 $\pm$ 2 (148.4)	98 $\pm$ 12 (1187.5)	109.4 $\pm$ 15 (9.3)	95 $\pm$ 7 (148.4)	102 $\pm$ 8 (1187.5)
16	4(<i>RS</i>)-ST- Δ^5 -8-NeuroF	107 $\pm$ 10 (296.9)	95 $\pm$ 15 (1187.5)	94 $\pm$ 7 (4750)	109 $\pm$ 6 (296.9)	85 $\pm$ 14 (1187.5)	100 $\pm$ 13 (4750)
17	17-F _{2t} -dihomo-IsoP + 17- <i>epi</i> -17-F _{2t} -dihomo-IsoP	90 $\pm$ 14 (1.2)	97 $\pm$ 6 (74.2)	101 $\pm$ 3 (2375)	103 $\pm$ 12 (1.2)	95 $\pm$ 1 (74.2)	103 $\pm$ 3 (2375)
19	<i>ent</i> -7(<i>RS</i>)-F _{2t} -dihomo-IsoP	86 $\pm$ 20 (0.6)	98 $\pm$ 10 (37.1)	101 $\pm$ 13 (1187.5)	99.1 $\pm$ 11 (0.6)	98 $\pm$ 7 (37.1)	101.8 $\pm$ 9 (1187.5)
20	17(<i>RS</i>)-10- <i>epi</i> -SC- Δ^{15} -11-dihomo-IsoF	120 $\pm$ 20 (0.6)	87 $\pm$ 8 (37.1)	107 $\pm$ 14 (1187.5)	130 $\pm$ 17 (0.6)	86 $\pm$ 5 (37.1)	106 $\pm$ 9 (1187.5)
21	7(<i>RS</i>)-ST- Δ^8 -11-dihomo-IsoF	88 $\pm$ 15 (148.4)	88 $\pm$ 13 (1187.5)	112 $\pm$ 12 (4750)	95 $\pm$ 15 (148.4)	85 $\pm$ 12 (1187.5)	104 $\pm$ 11 (4750)
3	15-keto-15-F _{2t} -IsoP	99.1 $\pm$ 18 (1.2)	106 $\pm$ 5 (37.1)	98 $\pm$ 3 (1135.2)	103 $\pm$ 20 (1.2)	104 $\pm$ 5 (5.1)	100 $\pm$ 4 (1187.5)
18	1a,1b-dihomo-PGF _{2α}	108 $\pm$ 20 (1.2)	80 $\pm$ 10 (10)	106 $\pm$ 1 (1187.5)	118 $\pm$ 15 (1.2)	81 $\pm$ 6 (37.1)	107 $\pm$ 3 (1187.5)
5	15-F _{2t} -IsoP	108 $\pm$ 18 (2.3)	108 $\pm$ 6 (37.1)	102 $\pm$ 4 (1187.5)	90 $\pm$ 20 (1.2)	107 $\pm$ 4 (37.1)	100 $\pm$ 4 (1187.5)
8	15-E _{2t} -IsoP	88 $\pm$ 2 (9.3)	97 $\pm$ 3 (74.2)	101 $\pm$ 4 (1187.5)	100 $\pm$ 20 (1.2)	102 $\pm$ 20 (74.2)	100 $\pm$ 3 (1187.5)
6	11 β -PGF _{2α}	103 $\pm$ 1 (1.2)	100 $\pm$ 2 (37.1)	103 $\pm$ 3 (1187.5)	93 $\pm$ 12 (1.2)	104 $\pm$ 5 (37.1)	100 $\pm$ 3 (1187.5)
4	15- <i>epi</i> -15-F _{2t} -IsoP	115 $\pm$ 1 (2.3)	101 $\pm$ 7 (74.2)	100 $\pm$ 2 (1187.5)	115 $\pm$ 17 (2.3)	100 $\pm$ 7 (74.2)	101 $\pm$ 2 (1187.5)
10	6-keto-PGF _{1α}	82 $\pm$ 6 (0.6)	101 $\pm$ 3 (37.1)	102 $\pm$ 1 (1187.5)	84 $\pm$ 15 (0.6)	105 $\pm$ 5 (37.1)	100 $\pm$ 3 (1187.5)
7	PGF _{2α}	112 $\pm$ 8 (9.3)	100 $\pm$ 1 (148.4)	97 $\pm$ 2 (1187.5)	120 $\pm$ 12 (9.3)	97 $\pm$ 3 (148.4)	99 $\pm$ 3 (1187.5)
11	15-keto-15-E _{2t} -IsoP	118 $\pm$ 9 (2.3)	102 $\pm$ 3 (74.2)	102 $\pm$ 4 (1187.5)	110 $\pm$ 20 (2.3)	104 $\pm$ 5 (74.2)	100 $\pm$ 4 (1187.5)
9	PGE ₂	90 $\pm$ 12 (2.3)	98 $\pm$ 4 (74.2)	98 $\pm$ 2 (1187.5)	88 $\pm$ 8 (2.3)	102 $\pm$ 15 (74.2)	97 $\pm$ 2 (1187.5)

Note: Values within brackets indicate the concentration of each metabolite in the standard solution; ^a indicates the peak number according to

Figure 1

Table 4. Back-calculated intra- and inter-day accuracy and precision in spiked plasma samples.

# ^a	Analyte	Extraction yield				Matrix effect				Method			
		Accuracy ± RSD (conc nM)				% Accuracy ± RSD (conc nM)				Accuracy ± RSD (conc nM)			
		Intra-day (N=3)		Inter-day (N=2)		Intra-day (N=3)		Inter-day (N=2)		Intra-day (N=3)		Inter-day (N=2)	
		Low	High	Low	High	Low	High	Low	High	Low	High	Low	High
1	5-F _{2t} -IsoP + 5- <i>epi</i> -5-F _{2t} -IsoP	104 ± 13 (15)	91 ± 14 (1800)	93 ± 16 (15)	87 ± 7 (1800)	83 ± 11 (15)	86 ± 13 (1800)	95 ± 20 (15)	109 ± 3 (1800)	110 ± 4 (15)	105 ± 4 (1800)	110 ± 4 (15)	105 ± 4 (1800)
2	15- <i>epi</i> -2,3-dinor-15-F _{2t} -IsoP + 2,3-dinor-11β-PGF _{2α} + 2,3-dinor-15F _{2α} -IsoP	110 ± 13 (15)	95 ± 8 (1800)	98 ± 17 (15)	93 ± 2 (1800)	79 ± 9 (15)	92 ± 8 (15)	96 ± 20 (15)	100 ± 11 (1800)	95 ± 3 (15)	95 ± 4 (1800)	95 ± 8 (15)	97 ± 10 (1800)
12	4-F _{4t} -NeuroP + 4- <i>epi</i> -4-F _{4t} -NeuroP	89 ± 12 (15)	103 ± 18 (1800)	81 ± 14 (15)	94 ± 14 (1800)	100 ± 15 (15)	89 ± 17 (1800)	109 ± 15 (15)	104 ± 20 (1800)	109 ± 5 (15)	119 ± 7 (1800)	100 ± 20 (15)	113 ± 10 (1800)
13	10- <i>epi</i> -10-F _{4t} -NeuroP	87 ± 13 (5)	95 ± 15 (600)	81 ± 9 (5)	91 ± 6 (600)	102 ± 19 (5)	96 ± 15 (600)	120 ± 20 (5)	109 ± 18 (600)	98 ± 14 (5)	116 ± 12 (600)	94 ± 17 (5)	113 ± 10 (600)
14	10-F _{4t} -NeuroP	90 ± 20 (5)	95 ± 15 (600)	81 ± 16 (5)	90 ± 8 (600)	83 ± 17 (5)	94 ± 16 (600)	97 ± 18 (5)	109 ± 19 (600)	87 ± 9 (5)	101 ± 3 (600)	89 ± 11 (5)	106 ± 10 (600)
15	14(RS)-14-F _{4t} -NeuroP	71 ± 30 (5)	94 ± 15 (600)	110 ± 51 (5)	89 ± 7 (600)	70 ± 30 (5)	86 ± 4 (600)	50 ± 27 (5)	80 ± 10 (600)	106 ± 41 (5)	94 ± 4 (600)	89 ± 36 (5)	90 ± 30 (600)
16	4(RS)-ST-Δ ⁵ -8-NeuroF	<LOD (5)	105 ± 16 (600)	<LOD (5)	131 ± 30 (600)	<LOD (5)	70 ± 30 (600)	<LOD (5)	80 ± 20 (600)	<LOQ (5)	70 ± 20 (600)	<LOQ (5)	110 ± 40 (600)
17	17-F _{2t} -dihomo-IsoP + 17- <i>epi</i> -17-F _{2t} - dihomo-IsoP	64 ± 9 (10)	73 ± 15 (1200)	61 ± 8 (10)	72 ± 2 (1200)	114 ± 14 (10)	90 ± 18 (1200)	123 ± 14 (10)	100 ± 16 (1200)	78 ± 8 (10)	85 ± 8 (1200)	67 ± 20 (10)	85 ± 9 (1200)
19	ent-7(RS)-F _{2t} -dihomo-IsoP	70 ± 11 (5)	81 ± 14 (600)	64 ± 12 (5)	76 ± 9 (600)	89 ± 18 (5)	82 ± 14 (600)	92 ± 13 (5)	92 ± 15 (600)	65 ± 6 (5)	88 ± 8 (600)	59 ± 11 (5)	85 ± 9 (600)
20	17(RS)-10- <i>epi</i> -SC-Δ ¹⁵ -11-dihomo-IsoF	78 ± 19 (5)	90 ± 15 (600)	73 ± 11 (5)	86 ± 7 (600)	110 ± 30 (5)	94 ± 17 (600)	116 ± 20 (5)	107 ± 18 (600)	83 ± 32 (5)	108 ± 9 (600)	78 ± 30 (5)	106 ± 10 (600)
21	7(RS)-ST-Δ ⁸ -11-dihomo-IsoF	87 ± 17 (5)	100 ± 17 (600)	<LOD (5)	95 ± 6 (600)	<LOD (5)	116 ± 20 (600)	<LOD (5)	131 ± 30 (600)	<LOQ (5)	65 ± 20 (600)	<LOQ (5)	84 ± 30 (600)
3	15-keto-15-F _{2t} -IsoP	<LOD (5)	<LOD (600)	<LOD (5)	<LOD (600)	<LOD (5)	85 ± 13 (600)	<LOD (5)	101 ± 20 (600)	<LOQ (5)	<LOQ (600)	<LOQ (5)	<LOQ (600)
18	1a,1b-dihomo-PGF _{2α}	52 ± 11 (5)	62 ± 11 (600)	<LOD (5)	60 ± 5 (600)	150 ± 40 (5)	107 ± 20 (600)	180 ± 40 (5)	120 ± 20 (600)	33 ± 6 (5)	72 ± 5 (600)	38 ± 13 (5)	77 ± 10 (600)
5	15-F _{2t} -IsoP	82 ± 16 (5)	97 ± 11 (600)	79 ± 5 (5)	87 ± 16 (600)	95 ± 20 (5)	86 ± 10 (600)	101 ± 15 (5)	101 ± 18 (600)	87 ± 15 (5)	99 ± 1 (600)	86 ± 18 (5)	99 ± 10 (600)
8	15-E _{2t} -IsoP	<LOD (5)	<LOD (600)	<LOD (5)	<LOD (600)	<LOD (5)	83 ± 15 (600)	<LOD (5)	130 ± 9 (600)	<LOQ (5)	<LOQ (600)	<LOQ (5)	<LOQ (600)
6	11β-PGF _{2α}	100 ± 20 (5)	96 ± 14 (600)	80 ± 30 (5)	88 ± 13 (600)	100 ± 20 (5)	89 ± 14 (600)	120 ± 30 (5)	104 ± 19 (600)	89 ± 6 (5)	99 ± 1 (600)	84 ± 13 (5)	100 ± 10 (600)
4	15- <i>epi</i> -15-F _{2t} -IsoP	101 ± 15 (5)	106 ± 17 (600)	90 ± 20 (5)	95 ± 15 (600)	87 ± 10 (5)	125 ± 2 (600)	75 ± 15 (5)	100 ± 20 (600)	111 ± 12 (5)	96 ± 5 (600)	102 ± 13 (5)	101 ± 10 (600)
10	6-keto-PGF _{1α}	107 ± 16 (5)	87 ± 13 (600)	95 ± 18 (5)	87 ± 1 (600)	97 ± 17 (5)	100 ± 2 (600)	85 ± 17 (5)	92 ± 10 (600)	79 ± 12 (5)	91 ± 2 (600)	80 ± 8 (5)	94 ± 10 (600)
7	PGF _{2α}	115 ± 11 (5)	94 ± 15 (600)	106 ± 12 (5)	86 ± 14 (600)	34 ± 8 (5)	82 ± 10 (600)	32 ± 10 (5)	100 ± 20 (600)	120 ± 16 (5)	103 ± 6 (600)	100 ± 18 (5)	102 ± 10 (600)
11	15-keto-15-E _{2t} -IsoP	<LOD (5)	<LOD (600)	<LOD (5)	<LOD (600)	119 ± 16 (5)	129 ± 1 (600)	110 ± 20 (5)	100 ± 30 (600)	<LOQ (5)	<LOQ (600)	<LOQ (5)	<LOQ (600)
9	PGE ₂	<LOD (5)	<LOD (600)	<LOD (5)	<LOD (600)	90 ± 20 (5)	78 ± 11 (600)	100 ± 20 (5)	93 ± 17 (600)	<LOQ (5)	<LOQ (600)	<LOQ (5)	<LOQ (600)

Note: Values within brackets indicate the added concentration of each metabolite added to the plasma sample; ^a indicates the peak number

according to Figure 1.

Table 5. Main descriptors of the distribution of concentrations (nM) of the lipid peroxidation products in plasma samples with concentrations >LOQ from newborns with HIE.

# ^a	Analyte	Range	Median	IQR (25-75)	Mean ± s	>LOQ (%)
1	5-F _{2t} -IsoP + 5- <i>epi</i> -5-F _{2t} -IsoP	0.5 – 8.6	3.2	1.9	3.5 ± 1.3	44
2	15- <i>epi</i> -2,3-dinor-15-F _{2t} -IsoP + 2,3-dinor-11β-PGF _{2α} + 2,3-dinor-15-F _{2α} -IsoP	-	-	-	-	0
12	4-F _{4t} -NeuroP + 4- <i>epi</i> -4-F _{4t} -NeuroP	1.1 – 1.6	1.3	0.2	1.3 ± 0.2	7
13	10- <i>epi</i> -10-F _{4t} -NeuroP	0.4 – 0.8	0.4	0.1	0.5 ± 0.1	9
14	10-F _{4t} -NeuroP	0.4 – 0.8	0.5	0.09	0.53 ± 0.12	13
15	14(<i>RS</i>)-14-F _{4t} -NeuroP	-	-	-	-	0
16	4(<i>RS</i>)-ST-Δ ⁵ -8-NeuroF	-	-	-	-	0
17	17-F _{2t} -dihomo-IsoP + 17- <i>epi</i> -17-F _{2t} -dihomo-IsoP	0.5 – 1.1	0.8	0.1	0.8 ± 0.2	5
19	<i>ent</i> -7(<i>RS</i>)-F _{2t} -dihomo-IsoP	0.3 – 1.0	0.5	0.1	0.5 ± 0.2	4
20	17(<i>RS</i>)-10- <i>epi</i> -SC-Δ ¹⁵ -11-dihomo-IsoF	0.4 – 3.2	0.6	0.4	0.8 ± 0.6	61
21	7(<i>RS</i>)-ST-Δ ⁸ -11-dihomo-IsoF	89.9 – 900.7	174.5	151.7	240 ± 170	74
18	1a,1b-dihomo-PGF _{2α}	0.8 -2.9	1.1	0.45	1.2 ± 0.4	37
5	15-F _{2t} -IsoP	-	-	-	-	0
6	11β-PGF _{2α}	-	-	-	-	0
4	15- <i>epi</i> -15-F _{2t} -IsoP	-	-	-	-	0
10	6-keto-PGF _{1α}	0.4 – 0.8	0.5	0.1	0.6 ± 0.1	3
7	PGF _{2α}	0.8 – 10.8	2.5	1.2	2.6 ± 1.1	98
-	Isoprostanes ^b	-	-	-	-	0
-	Isofurans ^b	19.8 – 184.5	52.1	50	70 ± 40	76
-	Neuroprostanes ^b	20 – 114	50.3	23	50 ± 20	29
-	Neurofurans ^b	8 – 27	14.5	7	15 ± 4	69

Note: ^a indicates the peak number according to Figure 1; ^b Values in area /area of internal standard x1000